A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension

European Journal of Ophthalmology

Volumn 18, Issue 3, 2008, Pages 408-416

  Goldberg, Iva ^a   Li, X Y ^b   Selaru, P ^c   Paggiarino, D ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ALLERGAN INC   (United States)

^c PFIZER INC   (United States)

Author keywords

Adverse events; Glaucoma; Iris pigmentation; Latanoprost; Ocular hypertension

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST;

ADOLESCENT; ADULT; AGED; ALLERGY; ANGINA PECTORIS; ARTICLE; ASTHMA; BRONCHITIS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHEST INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; DERMATITIS; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EYE COLOR; EYE DISEASE; EYE IRRITATION; EYELASH; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERPIGMENTATION; INCIDENCE; INSOMNIA; INTRAOCULAR HYPERTENSION; IRITIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPEN STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RISK ASSESSMENT; SCHOOL CHILD; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; THORAX PAIN; UVEITIS; VALVULAR HEART DISEASE;

EID: 54749133421     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800315     Document Type: Article

References (28)

1. Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000; 78: 71-6.
2. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol 2002; 240: 379-86.
3. Watson PG, the Latanoprost Study Group. Latanoprost: two years' experience of its use in the United Kingdom. Ophthalmology 1998; 105: 82-7.
4. Altintas O, Yuksel N, Karabas VL, Demirici G. Cystoid macular edema associated with latanoprost after uncomplicated cataract surgery. Eur J Ophthalmol 2005; 15: 158-61.
5. Avakian A, Renier SA, Butler PJ. Adverse effects of latanoprost on patients with medically resistant glaucoma. Arch Ophthalmol 1998; 116: 679-80.
6. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998; 126: 602-4.
7. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998; 126: 134-5.
8. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126: 37-41.
9. Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998; 116: 680-2.
10. Jager M, Jonas JB. Cystoid macular edema associated with latanoprost therapy in a pseudophakic vitrectomized patient after removal of silicone oil endotamponade. Eur J Ophthalmol 2003; 13: 221-2.
11. Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999; 106: 1024-9.
12. Thorne JE, Maguire AM, Lanciano R. CME and anterior uveitis with latanoprost use. Ophthalmology 1998; 105: 1981-3.
13. Wardrop DR, Wishart PK. Latanoprost and cystoid macutar oedema in a pseudophake. Br J Ophthalmol 1998; 82: 843-4.
14. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263-8.
15. Watanabe K, Hayasaka S, Hayasaka Y, Nagaki Y, Watanabe K. Cystoid macular edema associated with latanoprost use in a pseudophakic eye with a history of surgical complications. Jpn J Ophthalmol 2003; 47: 110-2.
16. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995; 102: 1743-52.
17. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37.
18. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47 (Suppl): S219-30.
19. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47 (Suppl): S6-12.
20. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multi-center trial in the United States. Ophthalmology 1996; 103: 138-47.
21. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996; 114: 929-32.
22. Linden C, Alm A. The effect on intraocular pressure of latanoprost once or four times daily. Br J Ophthalmol 2001; 85: 1163-6.
23. Alm A, Schoenfelder J, McDermott J. A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch Ophthalmol 2004; 122: 957-65.
24. Banerjee DK, Lee GS, Malik SK, Daly S. Underdiagnosis of asthma in the elderly. Br J Dis Chest 1987; 81: 23-29.
25. Hedner JA, Svedmyr N, Lunde H, Mandahl A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate steroid treated asthma. Surv Ophthalmol 1997; 41 (Suppl): S111-5.
26. Hedner J, Everts B, Moller, CS. Latanoprost and respiratory function in asthmatic patients. Arch Ophthalmol 1999; 117: 1305-9.
27. Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol 2002; 47 (Suppl): S219-30.
28. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol 2002; 47 (Suppl): S6-12.